TP53 and neoplasm: On the other hand, with codelivery of the p28-p14ARF protein, extending the dosing interval of p28-p53 to six days still resulted in considerable inhibition of subcutaneous HCT116 tumor growth in mice (Figure 3A,B and Figure S10A).